Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: Direct evidence from sympathetic neural recording

Acute Cardiac Care

Volumn 12, Issue 1, 2010, Pages 25-30

  Despas, Fabien ^a,b,c   Trouillet, Charlotte ^c   Franchitto, Nicolas ^a,b   Labrunee, Marc ^a,b   Galinier, Michel ^c   Senard, Jean Michel ^a,b,c   Pathak, Atul ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Heart failure; Nervous system; Pharmacology; Sympathetic

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DOBUTAMINE; LEVOSIMENDAN;

ACUTE HEART FAILURE; ADULT; ARTICLE; BLOOD PRESSURE FLUCTUATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART OUTPUT; HEART PERFORMANCE; HEART RATE; HEART STROKE VOLUME; HUMAN; LOADING DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; MUSCLE CONTRACTION; MUSCLE INNERVATION; NEUROGRAPHY; PLETHYSMOGRAPHY; PRIORITY JOURNAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYMPATHETIC NERVE; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE;

ACUTE DISEASE; CARDIOTONIC AGENTS; DRUG MONITORING; ECHOCARDIOGRAPHY; ELECTROMYOGRAPHY; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; MALE; MICROELECTRODES; MIDDLE AGED; PLETHYSMOGRAPHY; PYRIDAZINES; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 77749261050     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.3109/17482940903434077     Document Type: Article

References (27)

1. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J. 2005;149:209-16.
2. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The task force on acute heart failure of the European Society of Cardiology. Eur Heart J. 2005;26:384-416.
3. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure - a meta-regression analysis. Eur J Heart Fail. 2002;4:515-29.
4. Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study. Am Heart J. 2002;144:1102-8.
5. Pathak A, Velez-Roa S, Xhaet O, Najem B, van de Borne P. Dose-dependent effect of dobutamine on chemoreflex activity in healthy volunteers. Br J Clin Pharmacol. 2006;62:272-9.
6. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol.1995;25:794-801.
7. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2 sensitizer, activates the glibenclamide-sensitive K channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249-59.
8. Kaheinen P, Pollesello P, Hertelendi Z, Borbely A, Szilagyi S, Nissinen E, et al. Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2-sensitizing effect but not to stereoselective phosphodiesterase inhibition. Basic Clin Pharmacol Toxicol. 2006;98:74-8.
9. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903-12.
10. Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol. 2006; 98:1641-5.
11. Grassi G, Bolla G, Quarti-Trevano F, Arenare F, Brambilla G, Mancia G. Sympathetic activation in congestive heart failure: Reproducibility of neuroadrenergic markers. Eur J Heart Fail. 2008;10:1186-91.
12. Despas F, Detis N, Dumonteil N, Labrunee M, Bellon B, Franchitto N, et al. Excessive sympathetic activation in heart failure with chronic renal failure: Role of chemoreflex activation. J Hypertens. 2009;27:1849-54.
13. Vallbo AB, Hagbarth KE, Wallin BG. Microneurography: how the technique developed and its role in the investigation of the sympathetic nervous system. J Appl Physiol. 2004; 96:1262-9.
14. Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol. 1994;46:191-6.
15. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8:105-10.
16. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial. JAMA 2007;297:1883-91.
17. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg. 2000;90:5-11.
18. La Rovere MT, Pinna GD, Maestri R, Robbi E, Caporotondi A, Guazzotti G, et al. Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. J Am Coll Cardiol. 2009;53:193-9.
19. Hainsworth R. Reflexes from the heart. Physiol Rev. 1991; 71:617-58.
20. al-Timman JK, Hainsworth R. Reflex vascular responses to changes in left ventricular pressures, heart rate and inotropic state in dogs. Exp Physiol. 1992;77:455-69.
21. Fitzpatrick AP, Banner N, Cheng A, Yacoub M, Sutton R. Vasovagal reactions may occur after orthotopic heart transplantation. J Am Coll Cardiol. 1993;21:1132-7.
22. Parissis JT, Karavidas A, Bistola V, Arapi S, Paraskevaidis IA, Farmakis D, et al. Effects of levosimendan on flowmediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis 2008;197:278-82.
23. Miura T, Kawamura S, Tatsuno H, Ikeda Y, Mikami S, Iwamoto H, et al. Ischemic preconditioning attenuates cardiac sympathetic nerve injury via ATP-sensitive potassium channels during myocardial ischemia. Circulation 2001; 104:1053-8.
24. Abramson BL, Ando S, Notarius CF, Rongen GA, Floras JS. Effect of atrial natriuretic peptide on muscle sympathetic activity and its reflex control in human heart failure. Circulation 1999;99:1810-5.
25. Floras JS. Inhibitory effect of atrial natriuretic factor on sympathetic ganglionic neurotransmission in humans. Am J Physiol. 1995;269:R406-12.
26. Parissis JT, Andreadou I, Markantonis SL, Bistola V, Louka A, Pyriochou A, et al. Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis 2007;195:e210-5.
27. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol. 2004;93:1309-12.